Noah Biotech

Noah Biotech is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of mRNA-based vaccines and therapeutics. The company leverages its proprietary lipid nanoparticle (LNP) delivery platform and advanced mRNA synthesis technology to address unmet needs in infectious diseases and oncology. Its lead program, NB-001, is an mRNA vaccine for COVID-19 currently in clinical development, supported by a robust pipeline including candidates for respiratory syncytial virus (RSV), influenza, and shingles. Additionally, Noah Biotech is exploring personalized cancer vaccines and protein replacement therapies to expand its therapeutic reach. The company is backed by prominent venture capital firms, including Matrix Partners China and GL Ventures, and operates its own GMP-compliant manufacturing facilities. Noah Biotech aims to establish itself as a leader in the global mRNA landscape through continuous innovation in delivery systems and sequence optimization.